Page 93 - Genentech News Today

AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) ("Anebulo"), today announced the appointment of Bimal Shah to its Board of Directors. Mr. Shah will serve...

LEXINGTON, Mass., Oct. 6, 2023 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on...

Weight-loss treatments aren’t the only big deal in medicine. Our 2023 healthcare roundtable explores the best investing opportunities.

<p>In a study led by investigators from <a href="https://www.massgeneralbrigham.org/" target="_blank">Mass General Brigham</a>, <a href="https://wyss.harvard.edu/" target="_blank">the Wyss Institute for Biologically Inspired Engineering at Harvard University</a> and <a href="https://www.dana-farber.org/" target="_blank">Dana-Farber Cancer Institute</a>, in collaboration with researchers from acr...

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023 Lausanne, Switzerland, October 5, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Management will present a corporate overview and participate in one-on-one investor meetings during the Jefferies 2023 CNS & Neuro Summit, taking place in-person in New York City on October 11-12, 2023...

The CEO of Moderna speaks with WebMD CMO John Whyte, MD, MPH, about the potential of mRNA technology and much more.

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update regarding...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the results of imaging analyses...

​​​​​​​On September 29, 2023, Biogen announced the FDA approval of TOFIDENCE (tocilizumab-bavi) intravenous formulation which is the first tocilizumab biosimilar approved by the FDA in...

The US Court of Appeals for the Federal Circuit invalidated yet another set of antibody genus claims, finding the case “materially indistinguishable” from those in the 2023 Supreme...